09:52 AM EDT, 09/04/2024 (MT Newswires) -- Abbott Laboratories ( ABT ) said Wednesday it has started a study to assess the use of its deep brain stimulation system to manage treatment-resistant depression.

The US Food and Drug Administration has given Abbott breakthrough device designation to explore the use of the system to treat the disease, the company said.

The deep brain stimulation system sends small electrical pulses to specific parts of the brain with the goal of relieving symptoms, Abbott said.

Price: 114.55, Change: -0.11, Percent Change: -0.10